Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-17-002389
Filing Date
2017-09-15
Accepted
2017-09-15 13:40:24
Documents
34
Period of Report
2016-11-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q sibannac_10q-113016.htm 10-Q 117420
2 CERTIFICATION sibannac_10q-ex3101.htm EX-31.1 7264
3 CERTIFICATION sibannac_10q-ex3201.htm EX-32.1 3640
  Complete submission text file 0001683168-17-002389.txt   855959

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE snnc-20161130.xml EX-101.INS 65699
5 XBRL SCHEMA FILE snnc-20161130.xsd EX-101.SCH 12305
6 XBRL CALCULATION FILE snnc-20161130_cal.xml EX-101.CAL 26016
7 XBRL DEFINITION FILE snnc-20161130_def.xml EX-101.DEF 21656
8 XBRL LABEL FILE snnc-20161130_lab.xml EX-101.LAB 94077
9 XBRL PRESENTATION FILE snnc-20161130_pre.xml EX-101.PRE 74088
Mailing Address 2122 E. HIGHLAND AVENUE, SUITE 425 PHOENIX AZ 85016
Business Address 2122 E. HIGHLAND AVENUE, SUITE 425 PHOENIX AZ 85016 480-498-8300
Sibannac, Inc. (Filer) CIK: 0001313938 (see all company filings)

EIN.: 330903494 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 000-55578 | Film No.: 171087600
SIC: 2834 Pharmaceutical Preparations